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Abstract
Background: Dietary supplements may have adverse effects and potentially interact with 
conventional medications. They are perceived as “natural” products, free of side effects with 
no need for medical consultation. Little is known about consumption of dietary supplements by 
patients with cardiac diseases. The objective of this study was to investigate dietary supplement 
consumption among cardiac patients admitted to internal and cardiology wards. Potential 
drug-dietary supplement interactions were also assessed.
Methods: During a period of 6 months, patients with cardiac disease hospitalized in the 
Internal Medicine and Cardiology Wards at Assaf Harofeh Medical Center were evaluated 
regarding their dietary supplement consumption. A literature survey examining possible drug-
-supplement interaction was performed.
Results: Out of 149 cardiac patients, 45% were dietary supplement consumers. Patients ad-
mitted to the Internal Medicine Wards consumed more dietary supplements than those admit-
ted to the Cardiology Division. Dietary supplement consumption was associated with older age 
(OR = 1.05, p = 0.022), female gender (OR = 2.94, p = 0.014) and routine physical activity 
(OR = 3.15, p = 0.007). Diabetes mellitus (OR = 2.68, p = 0.020), hematological diseases 
(OR = 13.29, p = 0.022), and the use of anti-diabetic medications (OR = 4.28, p = 0.001) 
were independently associated with dietary supplement intake. Sixteen potential moderate in-
teractions between prescribed medications and dietary supplements were found.
Conclusions: Consumption of dietary supplements is common among cardiac patients. It is 
more common in those admitted to Internal Medicine Departments than in those admitted to 
the Cardiology Wards. Due to the risk of various drug-supplement interactions consumed by 
patients with cardiac diseases, there is a need to increase awareness and knowledge among 
medical staff regarding the intake of dietary supplements. (Cardiol J 2015; 22, 5: 510–518)
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Introduction
The use of dietary supplements/vitamins/ 
/medicinal plants (hereinafter: dietary supplements) 
has increased consistently over the last few years. 
In the United States, 1 in 4 persons consuming 
prescription medications takes also dietary supple-
ments [1]. According to the Dietary Supplement 
Health and Education Act (DSHEA), the definition 
of a dietary supplement is: “a product that is intend-
ed to supplement the diet, contains one or more 
dietary ingredients (including vitamins, minerals, 
herbs or other botanicals, amino acids, and certain 
other substances) or their constituents, is intended 
to be taken by mouth, in forms such as tablets, 
capsules, powders, softgels, gelcaps, or liquids, 
and are labeled as being a dietary supplement” [2]. 
Dietary supplements have been authorized for use 
based on their proven pharmacological activity (in 
clinical studies) or according to ancient traditions 
and to the subjective sense of the user [1].
Dietary supplements can affect the absorp-
tion, metabolism, and disposition of other drugs 
[1]. Currently, there is no sufficient evidence-
based literature regarding the safety and efficacy 
of dietary supplements and of the possible dietary 
supplement-drug interactions. The regulations 
of the pre-clinical and clinical studies regarding 
dietary supplements are not as stringent as those 
testing conventional drugs, thus resulting in an 
increased risk of adverse effects.
Chronically ill patients are at a greater risk 
of these interactions due to the higher amount of 
prescription medications taken. This is especially 
true in narrow therapeutic range medications such 
as in seizure disorders, cardiac arrhythmias or con-
gestive heart failure. The addition of any substance 
could result in an unwanted outcome, thereby 
subjecting those patients to an increased risk of 
disease deterioration [3].
One of the most studied dietary supplements 
is omega 3. Most of the epidemiological and inter-
vention research studies that have been conducted 
on single cells, animals and humans have shown the 
advantageous effects of omega 3 on cardiovascular 
disease, including: various types of coronary heart 
disease, myocardial infarction, stroke, acute heart 
failure [4]. The use of omega 3 is currently recom-
mended by the American Heart Association [5], 
American College of Cardiology [6], and European 
Society of Cardiology [7] for reducing the risk of 
cardiovascular disease.
In a study conducted in Israel among 299 
patients, Goldstein et al. [8] reported that 19.3% 
of patients hospitalized for acute ischemic heart 
disease (IHD) as their leading diagnosis, consumed 
herbal supplements, compared to 31.1% of patients 
who had a history of IHD.
To the best of our knowledge, no study has 
been conducted in Israel and scarce data is avail-
able worldwide on “dietary supplement” intake in 
patients who suffer from various cardiac diseases. 
Thus, the aims of the current study were: A) To 
examine the characteristics of cardiac disease pa-
tients who consume dietary supplements and the 
frequency of their usage, B) To compare dietary 
supplement consumption in patients admitted to 
the Cardiology Division (the Intensive Care Cardiac 
Unit and the regular Cardiac Ward) and patients 
admitted to the Internal Medicine Wards, C) To 
search for potential adverse drug-supplement 
interactions.
Methods
The study included patients hospitalized with 
acute or chronic cardiac disease in the Internal 
Medicine Wards and the Cardiology Division at 
Assaf Harofeh Medical Center. Cardiac disease was 
defined as at least one of the following categories: 
IHD, congestive heart failure, valvular heart dis-
ease or arrhythmias. Children under the age of 
18 years; dementia or mechanical ventilated patients 
were excluded from the study. The study was au-
thorized by the Institutional Helsinki Committee 
and patients signed an informed consent form.
For each patient, the primary investigator or 
a pharmacist completed a questionnaire regarding 
demographics, medical history, medications and 
dietary supplements consumed on a regular basis.
Patients admitted to the Internal and Cardiol-
ogy Wards were compared.
A literature review (Stockley’s Drug Interac-
tions, Stockley’s Herbal Medicines Interactions, 
http://naturaldatabase.therapeuticresearch.com/) 
was conducted to explore the possibility of drug-
-supplement interactions.
Statistical analysis
Frequency and percentage were used to de-
scribe categorical variables (hospitalization ward, 
gender, religion, place of birth, family status, 
education, salary, physical activity, smoking, alco-
hol consumption, drug use, chronic diseases and 
medications). Continuous variables (age and body 
mass index) were examined for normal distribution 
using the Kolmogorov-Smirnov test and averages 
and standard deviations were computed. Univari-
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ate analysis was used to examine the relationship 
between categorical variables and the consump-
tion of dietary supplements (using the c2 test) 
and continuous variables between taking dietary 
supplements vs. not taking dietary supplements 
(by Student’s t-test). Multivariate analysis was 
conducted using the logistic regression analysis. 
Age, gender and variables that were associated 
with consumption of dietary supplements shown 
by the univariate analysis (p < 0.1) were entered 
to the regression. The regression was conducted 
using the backward method while age and gender 
were included by the Enter method. A p < 0.05 was 
defined as statistically significant. All statistical 
tests were 2-tailed. All analyses were performed 
with the SPSS 21.0 software.
Results
One hundred and forty-nine patients were 
enrolled. Patients’ demographic characteristics, 
habits and medical history are presented in Table 1. 
Thirty-two point nine percent of patients were ad-
mitted in Internal Medicine Wards and 67.1% were 
hospitalized in the Cardiology Division. Most of 
the patients were Jewish, born in Israel or Eastern 
Europe, married with at least 12 years of education, 
and with average salaries or above average.
Dietary supplements were consumed by 45% 
(n = 67) of the patients. The consumption was di-
vided as follows: 12.1% (n = 18) of all patients con-
sumed a single dietary supplement, 15.4% (n = 23) 
2 dietary supplements, 8.7% (n = 13) 3 dietary 
supplements, 3.1% (n = 5) 4 dietary supplements, 
2.7% (n = 4) 5 dietary supplements and 2.7% (n = 4) 
consumed 6 dietary supplements.
The frequency of dietary supplement con-
sumed by the patients according to supplement 
type is presented in Table 2.
The demographic characteristics, habits and 
medical history of patients consuming dietary 
supplements compared to the non-consumers are 
presented in Table 3. Consumers differed from 
non-consumers in age, gender, physical activity 
and smoking habits. Forty-nine point three percent 
of consumers were female in comparison to 24.4% 
in the non-consumer group and 35.6% in the total 
population of the study, 49.3% of consumers were 
physically active compared to 30.5% in the non-
-consumer group and 38.9% in the total study popu-
lation, and 53.7% of consumers were non-smokers 
compared to 30.5% in the non-consumer group and 
43.6% in the total study population. Notably, half of 
the supplement consumers suffered from a chronic 
IHD (49.3%) and/or diabetes mellitus (50.7%). 
Multivariate and backward regression analysis 
revealed that dietary supplement consumption was 
associated with older age (OR = 1.05, p = 0.022), 
Table 1. Demographic characteristics, habits and 
medical history of all the patients.
Characteristic Mean ± SD  
or n (%)
Age 11.14 ± 64.15
Body mass index 29.53 ± 4.88
Gender (females/males) 53 (35.6)/96 (64.4)
Hospitalization Ward (Internal 
Medicine/Cardiology)
49 (32.9)/100 (67.1)
Food supplements consumers 67 (45)
Religion (Jewish/Arabic) 133 (89.3)/16 (10.7)
Place of birth:
Israel 56 (37.6)
Eastern Europe 53 (35.6)
North Africa 20 (13.4)
Other 20 (13.4)
Family status:
Married 110 (73.8)
Single 2 (1.3)
Divorced 25 (16.8)
Widowed 12 (8.1)
Education:
No education 9 (6)
Elementary school 24 (16.1)
High school 57 (38.3)
Academic 59 (39.6)
Salary:
Significantly below average 5 (3.4)
Below average 20 (13.4)
Average 24 (16.1)
Above average 41 (27.5)
Significantly above average 59 (39.6)
Physical activity  
(active/non-active) 
58 (38.9)/91 (61.1)
Smoking:
Non smoker 65 (43.6)
Smoker 34 (22.8)
Past smoker 50 (33.6)
Routine alcohol consumption 10 (6.7)
Drug use 2 (1.3)
Acute ischemic heart disease 69 (46.3)
Chronic ischemic heart disease 73 (49.0)
Congestive heart failure 33 (22.1)
Valvular heart disease 12 (8.1)
Cardiac arrhythmia 38 (25.5)
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female gender (OR = 2.94, p = 0.014) and routine 
physical activity (OR = 3.15, p=0.007). Diabetes 
mellitus (OR = 2.68, p = 0.020), hematological 
diseases (OR = 13.29, p = 0.022), and the use of 
anti-diabetic medications (OR = 4.28, p = 0.001) 
were independently associated with dietary sup-
plement intake (Table 4).
A comparison of the demographic character-
istics, habits, medical history and chronic medica-
tions intake of the dietary supplement consuming 
patients according to the hospitalization ward 
(Internal Medicine vs. Cardiology) is presented in 
Table 5. Patients admitted to the Internal Medicine 
Wards were not significantly older (69.9 years 
vs. 66.5 years, p = 0.18), had more chronic IHD 
(66.7% vs. 35.1%, p = 0.01), diabetes mellitus 
(70.0% vs. 35.1%, p = 0.005), pulmonary diseases 
(23.3% vs. 2.7%, p = 0.018) and gastrointestinal 
diseases (33.3% vs. 10.8%, p = 0.024) than those 
admitted to the Cardiology Division. Also, those 
admitted to the Internal Medicine Wards received 
chronic treatment with calcium channel blockers, 
alpha-blockers, angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers, statins, 
and anti-diabetes medication at a greater rate than 
those admitted to the Cardiology Wards (53.3% vs. 
27.0%, p = 0.028; 40.0% vs. 8.1%, p = 0.002; 83.3% 
vs. 54.1%, p = 0.011; 90.0% vs. 62.2%, p = 0.009 
and 56.7% vs. 29.47%, p = 0.026, respectively). 
The admission diagnosis of acute IHD was the only 
variant found to be statistically significant in those 
admitted to the Cardiology Wards compared to Inter-
nal Medicine Wards (43.2% vs. 16.7%, p = 0.020).
Consumption of dietary supplements in pa-
tients hospitalized in Internal Medicine Wards was 
associated with age (OR = 1.08, p = 0.024) and 
the use of anti-diabetic medication (OR = 10.76, 
p = 0.005) (Table 6). Age (OR = 1.05, p = 0.036), fe-
male gender (OR = 2.74, p = 0.044), admission diag-
nosis other than acute IHD (OR = 3.45, p = 0.010), 
and the use of levothyroxine (OR = 16.28, 
p = 0.024) were found to be associated with dietary 
supplement consumption in patients hospitalizes 
in the Cardiology Division. Sixteen potential mod-
erate drug-dietary supplement interactions were 
found (Table 7). No severe potential interaction 
was noted.
Discussion
Our study shows that dietary supplements 
were consumed by 45% of cardiac patients and 
half of them suffered from a chronic IHD and/or 
diabetes. Most patients consuming dietary sup-
plements were Jewish, born in Israel or Eastern 
Europe, married, with an education level of at least 
high school, earning average or above average 
salaries, physically active, non-smokers and did 
not consume alcohol or drugs routinely. Patients 
consuming dietary supplements admitted to the 
Internal Medicine Wards were found to be older 
with a higher body mass index than those admitted 
to the Cardiology Division. This may be explained 
by the advanced ages and multiple chronic diseases 
and complications of patients admitted to Internal 
Medicine Wards. These data were supported by 
Goldstein et al. [8] who reported that females, 
married individuals, those earning an above aver-
age salary with a higher level of education and 
non-smokers, consumed more dietary supple-
ments. Moreover, the profile of dietary supplement 
consumption in the United States was found to be: 
female sex (52%), age of 50 years or older (35%), 
higher level of education (49%), and an average 
income (45%; $20,000–$49,000/year) with a rising 
tendency at the higher income levels [9, 10]. An 
Australian meta-analysis performed in 2010 by Bin 
et al. [11] reviewed 20 studies conducted world-
wide. The study revealed that 36% of patients with 
cardiac diseases consume dietary supplements. It 
was also found that those consuming dietary sup-
plements tended to take more than 1 supplement 
per day. Two of the reviewed studies demonstrated 
the use of 2 dietary supplements on average [12, 
13] while another observed the use of 3 supple-
ments per patient [14]. The most frequent dietary 
supplements consumed were multivitamins and 
Table 2. Frequency of dietary supplement  
consumption according to the supplement type.
Food supplement Number  
of users (%)
Vitamin D 36 (53.7)
Vitamin B12 26 (38.8)
Calcium 17 (25.4)
Iron 6 (9)
Omega 3 6 (9)
Vitamin B6 6 (9)
Multivitamin 6 (9)
Folic acid 5 (7.5)
Laxatives (mainly Senna based) 5 (7.5)
Vitamin C 4 (6)
Megagluflex  
(Chondroitin + Glucosamine)
4 (6)
Probiotics 4 (6)
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Table 3. Demographic characteristics, habits and medical history of patients consuming food  
supplement. Univariate analysis: comparison consumers and non-consumers.
Characteristic Consumers (n = 67)
Mean ± SD or n (%)
Non consumers (n = 82)
Mean ± SD or n (%)
P
Body mass index 29.51 ± 4.38 29.55 ± 5.28 0.956
Age 68.03 ± 10.42 60.99 ± 10.76 < 0.001*
Hospitalization Ward: 0.005*
Internal Medicine 30 (44.8) 19 (23.2)
Cardiology 37 (55.2) 63 (76.8)
Gender — female 33 (49.3) 20 (24.4) 0.002*
Family status: 0.064
Married 44 (65.7) 66 (80.5)
Divorced 16 (23.9) 9 (11)
Widowed 7 (10.4) 5 (6.1)
Single 0 (0.0) 2 (2.4)
Ethnic origin: 0.089
Jewish 63 (94.0) 70 (85.4)
Arabic 4 (6.0) 12 (14.6)
Education: 0.365
No education 3 (4.5) 6 (7.3)
Elementary school 8 (11.9) 16 (19.5)
High school  30 (44.8) 27 (32.9)
Academic 26 (38.8) 33 (40.2)
Salary: 0.619
Significantly below average 3 (4.5) 2 (2.4)
Below average 7 (10.4) 13 (15.9)
Average 9 (13.4) 15 (18.3)
Above average 18 (26.9) 23 (28.0)
Significantly above average 30 (44.8) 29 (35.4)
Birth place: 0.319
Israel 20 (29.9) 36 (43.9)
Eastern Europe 27 (40.3) 26 (31.7)
Northern Africa 9 (13.4) 11 (13.4)
Other 11 (16.4) 9 (11.0)
Routine physical activity 33 (49.3) 25 (30.5) 0.019*
Smoking: 0.023*
Non smoker 36 (53.7) 29 (35.4)
Current smoker 9 (13.4) 25 (30.5)
Past smoker 22 (32.8) 28 (34.1)
Admission diagnosis of acute IHD 21 (31.3) 48 (58.5) 0.001*
IHD 33 (49.3) 40 (48.8) 0.954
Congestive heart failure 14 (20.9) 19 (57.6) 0.739
Valvular heart disease 4 (6.0) 8 (9.8) 0.398
Cardiac arrhythmia 21 (31.3) 17 (20.7) 0.139
Diabetes mellitus 34 (50.7) 21 (25.6) 0.002*
*p value represents the statistically significant correlation compared to the patients not consuming dietary supplements; IHD — ischemic 
heart disease; SD — standard deviation
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Table 4. Demographic characteristics, habits and medical history of patients consuming food  
supplements. Multivariate analysis and backward regression analysis of age, gender, physical activity 
that were found to correlate significantly with I — medical condition and II — medications.
Variant Odds ratio 95% CI P*
I
Age [years] 1.05 1.01–1.09 0.022*
Female gender 2.94 1.25–6.67 0.014*
Routine physical activity 3.15 1.36–7.28 0.007*
Admission diagnosis other than acute ischemic heart disease 2.04 0.91–4.76 0.085
Diabetes mellitus 2.68 1.17–6.14 0.020*
Gastrointestinal disease 3.58 0.95–13.54 0.060
Hematological disease 13.29 1.46–121.50 0.022*
II
Age [years] 1.06 1.02–1.10 0.003*
Female gender 3.13 1.33–7.14 0.009*
Routine physical activity 3.07 1.38–6.81 0.006*
Use of anti-diabetic medication 4.28 1.75–10.45 0.001*
Levothyroxin use 8.27 0.89–76.8 0.063
*p value represents the statistically significant correlation compared to the patients not consuming dietary supplements; CI — confidence interval
minerals. The data from our study revealed that 
most of the patients consumed 1 or 2 dietary sup-
plements per day. Most of the patients consumed 
vitamin D, vitamin B12 or calcium.
Several moderate interactions were identified 
in our study. Interactions between vitamin D and 
conventional medications were found: vitamin D 
induces cytochrome P450 3A4 enzyme activity, 
which metabolizes atorvastatin in the gut. Thus, 
a combination of vitamin D and atorvastatin could 
reduce the bioavailability of the drug. Schwartz et al. 
[15] examined 16 patients with and without supple-
mented vitamin D and demonstrated that those who 
consumed vitamin D products significantly reduced 
the levels of atorvastatin active metabolites by 55%, 
while the levels of different components of choles-
terol did not change. High doses of vitamin D could 
cause hypercalcemia, which might increase the risk 
of fatal cardiac arrhythmias when administered with 
digoxin, thiazide diuretics or verapamil [15]. In this 
study, 26 (72.2% of vitamin D consumers) consumed 
vitamin D with statins.
Calcium supplements taken with levothy-
roxine were found to reduce the efficacy of the 
medication [16]. In vitro studies showed that 
levothyroxine adsorbs to calcium carbonate at low 
pH levels (as in the stomach) thereby deregulating 
its efficacy [17]. In this study, 3 patients (17.6% of 
calcium consumers) consumed calcium with levo-
thyroxine. We do not have information regarding 
the timing of consumption.
The effects of the interaction of fish oil (which 
includes omega 3) and warfarin have been exten-
sively studied, yet the data are contradictory. In 
2 different studies, fish oil consumption had no ef-
fect on bleeding time. However, Buckley et al. [18] 
presented a case report in which omega 3 signi-
ficantly increased bleeding time in patients 
who consumed warfarin when doubling the 
fish oil intake. It was suggested that the anti-
thrombotic activity mechanism applied to omega 
3 could contribute to the increased bleeding time 
observed. In the present study, 2 patients (33.3% 
of omega 3 consumers) consumed omega 3 with 
warfarin.
It is of note that in our group of cardiac pa-
tients (the whole study population), omega 3 was 
consumed by 9% of the patients and no bleeding 
tendency was observed.
In addition, aspirin (consumed by 21 patients) 
and H2 blockers (consumed by 1 patient) were 
found to reduce the absorption of vitamin B12 from 
the intestine (80.7% and 3.8%, respectively, of 
vitamin B12 consuming patients) [16]. Moreover, 
aspirin reduces the absorption of vitamin C by one 
third, yet the level aspirin itself is not affected by 
vitamin C (aspirin was consumed by 3 patients; 
75% of vitamin C consumers) [16].
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Table 5. Demographic characteristics, habits, medical history and conventional medication intake of 
patients consuming food supplement, admitted to the Internal Medicine Wards vs. Cardiology Division 
— univariate analysis.
Characteristic Internal Medicine Ward (n = 30)
Mean ± SD or n (%)
Cardiology Division (n = 37)
Mean ± SD or n (%)
P*
Average BMI 30.9 ± 4.8 28.3 ± 3.6 0.013*
Average age [years] 69.9 ± 10.2 66.5 ± 10.4 0.180
Gender: 0.912
Male 15 (50.0) 19 (51.4)
Female 15 (50.0) 18 (48.6)
Family status: 0.240
Single 0 (0.0) 0 (0.0)
Married  17 (56.7) 27 (73.0)
Divorced 8 (26.7) 8 (21.6)
Widowed 5 (16.7) 2 (5.4)
Ethnic origin: 0.318
Jewish 27 (90.0) 36 (97.3)
Arabic 3 (10.0) 1 (2.7)
Education: 0.199
No education 2 (6.7) 1 (2.7)
Elementary school 6 (20.0) 2 (5.4)
High school  13 (43.3) 17 (45.9)
Academic 9 (30.0) 17 (45.9)
Salary: 0.289
Significantly below average 1 (3.3) 2 (5.4)
Below average 1 (3.3) 6 (16.2)
Average 3 (10.0) 6 (16.2)
Above average 8 (26.7) 10 (27.0)
Significantly above average 17 (56.7) 13 (35.1)
Birth place: 0.434
Israel 6 (20.0) 14 (37.8)
Eastern Europe 14 (46.7) 13 (35.1)
Northern Africa 5 (16.7) 4 (10.8)
Other 5 (16.7) 6 (16.2)
Routine physical activity 14 (46.7) 19 (51.4) 0.703
Smoking: 0.557
No 14 (46.7) 22 (59.5)
Yes 5 (16.7) 4 (10.8)
In the past 11 (36.7) 11 (29.7)
Admission diagnosis of acute IHD 5 (16.7) 16 (43.2) 0.020*
Ischemic heart disease  20 (66.7) 13 (35.1) 0.010*
Congestive heart failure 8 (26.7) 6 (16.2) 0.295
Valvular heart disease 1 (3.3) 3 (8.1) 0.622
Cardiac arrhythmia 11 (36.7) 10 (27.0) 0.398
Diabetes mellitus 21 (70.0) 13 (35.1) 0.005*
Pulmonary disease 7 (23.3) 1 (2.7) 0.018*
Gastrointestinal disease 10 (33.3) 4 (10.8) 0.024*
Chronic renal failure 6 (20.0) 4 (10.8) 0.324
Hematologic disease 7 (23.3) 2 (5.4) 0.067
Aspirin intake 24 (80.0) 22 (59.5) 0.072
Calcium channel blocker intake 16 (53.3) 10 (27.0) 0.028*
ACE/ARB intake 25 (83.3) 20 (54.1) 0.011*
Alpha-blocker intake 12 (40.0) 3 (8.1) 0.002*
Statins 27 (90.0) 23 (62.2) 0.009*
Anti-diabetic medications intake 17 (56.7) 11 (29.7) 0.026*
Levothyroxin 3 (10.0) 5 (13.5) 0.722
*p value represents the statistically significant correlation comparing the dietary consumers in the Internal Wards with those in the Cardiology  
Division; ACE — angiotensin converting enzyme; ARB — angiotensin receptor blocker; BMI — body mass index; IHD — ischemic heart disease
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Table 6. Demographic characteristics, habits, medical history and conventional medication intake of 
patients consuming food supplement, admitted to the Internal Medicine Wards vs. Cardiology Division 
— multivariate analysis and backward regression analysis of factors having significant correlation with 
“Dietary Supplement” intake: I — Internal Medicine Ward, II — Cardiology Division.
Variant Odds ratio 95% CI P*
I
Age [years] 1.08 1.01–1.15 0.024*
Female gender 2.76 0.65-11.77 0.170 
Use of anti-diabetic medication 10.76 2.07-55.83 0.005*
II
Age [years] 1.05 1.00–1.10 0.036*
Female gender 2.74 1.03–7.31 0.044*
Admission diagnosis other than acute ischemic heart disease 3.45 0.11–0.74 0.010*
Use of levothyroxin 16.28 1.43–184.85 0.024*
*p value representing the statistically significant correlation comparing the dietary consumers in the Internal Wards with those in the Cardiol-
ogy Division; CI — confidence interval
Table 7. Dietary supplement-drug interactions.
Dietary supplement Interacting drug Type of interaction Details 
Vitamin D Atorvastatin Pharmacokinetic Vitamin D induces cytochrome P450 3A4 
enzyme activity which can reduce  
atorvastatins’ bioavailability
Vitamin D Digoxin Pharmacodynamic High doses of vitamin D can cause  
hypercalcemia and fatal cardiac  
arrhythmias with digoxin
Vitamin D Thiazide Pharmacodynamic Thiazides decrease urinary calcium  
excretion, which could lead to  
hypercalcemia if vitamin D supplements 
are taken concurrently
Vitamin D Verapamil Pharmacodynamic High doses of vitamin D can reduce  
the effectiveness of verapamil in atrial  
fibrillation
Calcium Levothyroxin Pharmacokinetic Levothyroxine binds to calcium  
carbonate at low pH levels (as in the 
stomach) thereby lowering its efficacy
Omega 3 Warfarin Pharnakodynamic Omega 3 fatty acids are considered to 
have some antiplatelet activity, and may 
prolong the bleeding time. Also, may  
reduce levels of some coagulation  
factors. Used with warfarin may  
increase bleeding risk
Vitamin B12 Aspirin Pharmacokinetic Aspirin and H2 blockers reduce the  
absorption of vitamin B12 from  
the intestine
Vitamin B12 H2 blockers Pharmacokinetic
Vitamin C Aspirin Pharmacokinetic Aspirin reduces the absorption of  
vitamin C by one third
Limitations of the study
The study was conducted in one medical cent-
er with its own hospitalization admittance criteria 
to the different wards. Not all admitted patients 
were included in the study. Some of the patients 
could not participate in the study due to their health 
status and therefore the research population does 
not represent a complete picture of the hospitalized 
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Orith Karny-Rahkovich et al., Dietary supplement consumption among cardiac patients
patient population. This could affect the incidence 
results of dietary supplement use and possibly also 
of interactions between them and the conventional 
medications that have possibly been overlooked.
The patients examined were hospitalized in 
wards with an internal profile nature (Internal 
Departments and the Cardiology Division). The 
results might possibly have been different, to 
a certain degree, had we included patients hospital-
ized in the surgical units.
Conclusions
Most patients suffering from a heart disease 
consume 1 or 2 dietary supplements per day. More 
patients admitted to the Internal Medicine Wards 
consumed dietary supplements than those admit-
ted to the Cardiology Division. Physical activity, 
hematological disease history, age, female gender 
and the use of anti-diabetic medications were found 
to be significantly associated with dietary supple-
ment consumption.
Although potential life-threatening interac-
tions were not found in our study, there is a need to 
increase awareness and knowledge among medical 
staff regarding the intake of dietary supplements. 
Moreover, further studies focusing on the relation-
ship between dietary supplement intake and medi-
cations for various chronic diseases are needed.
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